Sakar Healthcare, a research-driven oncology orals and injection manufacturing company, has reported that its net profit in the June quarter doubled to ₹10 crore against ₹5 crore logged in the same period last year, on the back of strong demand.Revenue increased 38 per cent to ₹73 crore, reflecting 38 per cent YoY growth of ₹53 crore in Q1 FY26 on the back of entry into the new market and rise in demand.EBITDA was up 67 per cent ₹21 crore.Sanjay Shah, Managing Director said the enhanced profitability was due to commercial engagements, strengthened export momentum and advanced dossier submissions, Marketing Authorizations, site variation approvals and technology transfer projects with leading global pharmaceutical partners.“We also enhanced our integrated oncology platform by expanding our portfolio of in-house APIs supported by key regulatory certifications, reinforcing our capabilities and long-term competitive position,” he added.Looking ahead, the company remains confident of converting regulatory approvals into commercial launches and supplies, alongside growing export opportunities and the gradual ramp-up of oncology volumes, which will improve capacity utilisation and operating leverage.“Our long-term outlook remains promising, underpinned by the scalability of our oncology platform and the progressive commercialisation of our product portfolio,” he said.The company executed over 65 oncology product contracts, with over 50 commercial discussions currently underway.It shared dossiers for 21 of the 32 developed oncology products, securing 16 dossier approvals.The company completed 26 EU Marketing Authorisation filings, including 15 owned filings.The company developed 21 APIs in-house, including, 16 APIs with Written Confirmation, 8 Commercialised products, 2 API’s with CEP approval, 5 CEP applications currently in process.It has been pursuing 33 technology transfer projects for oncology products with Accord-Intas, Torrent in the UK and Germany, Emcure, Glenmark and Zydus. Of these projects, 7 have received site variation approvals—two in the UK and five in the EU.Published on July 27, 2026